Label-free and iPS Cell Technology Join Forces for Neurological Drug Discovery. Read how researchers performed robust, reproducible phenotypic screening using iCell Neurons, a label-free whole-cell assay, and an automated liquid handler.
Morgan HM, Haenel F, et al. (2014) Drug Discovery & Development.
FutureTox II (Jan 16 – 17, Chapel Hill, NC). Attend the CDI
presentation, Pluripotent Stem Cell Models—Reprogramming,
Differentiation, and Application in Toxicology
(Jan 16, 10:45 – 11:15 am).
SLAS2014 (Jan 18 – 22, San Diego, CA, Booth
1505). Join us at the Sanford Burnham satellite symposium, our customer reception, as well as
2 tutorials, 8 posters, and 3 podium presentations
featuring iCell methods and data.
ISSCR 2014 (Jun 18 – 21, Vancouver, Canada). Submit your abstract today! Submission deadline is Feb 11.
Nestlé in Biotech Deal to Test Foods on Human Cells. Nestlé Institute for Health Sciences will use CDI’s iCell and MyCell human cells to study the link between nutrition and diseases such as obesity and diabetes.
Wall Street Journal Article>> | Press Release>>
The Hamner Institutes and Cellular Dynamics Collaborate to Develop In Vitro Assays Using Human iPS Cell-derived Hepatocytes. Once validated, these assays should enable chemical, environmental, and pharmaceutical toxicity testing and risk assessments of compounds based on in vitro results, without progressing to studies in animals.
Jain Foundation Signs Agreement with Cellular Dynamics to Create iPSC Lines from Patients with Muscular Dystrophies. CDI will create 5 induced pluripotent stem cell (iPSC) lines from individuals with dystrophies caused by dysferlin protein deficiency. These patient-derived iPSC lines will be used as disease models for basic research and drug discovery.